Official medication data for Duchenne

• Effectiveness has been assessed in clinical studies including the Phase 3 EPIDYS trial and long-term data presented at the 2026 MDA conference.
• Official analyses indicate slower functional decline, including walking-related measures, and reduced muscle fat infiltration on imaging-based analyses.
• Additional conference analyses suggest a possible positive effect on preserving ambulation for longer.
• Safety requires monitoring of platelets, triglycerides and gastrointestinal effects, but the safety profile is described as manageable with monitoring.

At this stage, DUVYZAT is viewed as a progression-slowing therapy rather than a cure.

• Effectiveness has been evaluated both in the original randomized trial and in long-term GUARDIAN / real-world analyses presented at MDA 2026.
• Official long-term data suggest motor effectiveness comparable to classic corticosteroids on time to loss of ambulation.
• The same official package reported less vertebral fracture burden, markedly less cataract signal and a height advantage versus classic corticosteroids.
• This matters because many families compare AGAMREE and vamorolone under different names even though they refer to the same medicine.

At this stage, AGAMREE is viewed as a modern corticosteroid option that aims to preserve efficacy while reducing part of the classic steroid burden.

• EMFLAZA is one of the standard corticosteroid medicines used in Duchenne care and is officially labeled in the United States for patients aged 2 years and older.
• In practice, deflazacort is used to help preserve strength, daily function and ambulation for longer, while also remaining part of the background treatment environment against which newer medicines are often studied.
• Because it is a corticosteroid, families still need physician supervision for well-known steroid-related risks and long-term trade-offs.

At this stage, EMFLAZA is viewed as an established standard-of-care steroid rather than a new disease-specific innovation.

• ELEVIDYS is a gene therapy and not a standard oral background treatment. Its current FDA indication is limited to ambulatory patients aged 4 years and older with a confirmed DMD mutation.
• Official three-year EMBARK topline results reported slower decline on key functional measures in ambulatory Duchenne patients.
• At the same time, the FDA added a boxed warning for acute serious liver injury and acute liver failure and revised the indication after safety concerns in non-ambulatory patients.

At this stage, ELEVIDYS is viewed as a highly specialized option that requires careful eligibility and safety evaluation, not a universal Duchenne medicine for everyone.